Highlights for September 2017

  1. Zydus Cadila inks deal to produce varicella vaccine in Russia
  2. Fosun now aims for smaller Gland Pharma stake in $1.1B deal
  3. Panacea Biotec ties up with Canada’s Apotex to launch Prasugrel drug in US
  4. Eris Lifesciences acquires UTH Healthcare for ₹12.85 crore
  5. Strides Shasun' arm Arrow Pharmaceuticals has acquired Australian operations of Amneal
  6. Selexis and OSE Immunotherapeutics expand strategic alliance
  7. Axxam signs up for CNS collaboration with French pharma major
  8. Merck, looking to build on cancer success, buys I-O biotech Rigontec
  9. Boehringer, Gubra strike backloaded €250M obesity deal
  10. Catalent doubles down on biologics with $950M deal for Cook Pharmica
  11. Janssen deal gives new kid in town Provention two immune candidates
  12. Arcus' cancer portfolio attracts $35M option deal from Japan's Taiho
  13. NewLink inks deal to evaluate I-O-based combinations

For more such news and updates, please join our Group "Global Life Science Business Partnering" on LinkedIn.

 

Updates at Aagami:

  • A Happy client gives a long mandate for partnering in Asia region. Client is a Netherlands HQ'd company with a First-in-class phase-3-ready drug candidate for Post Operative Fibrosis (POF) with impeccable results
  • JRF Global and Aagami conducted seminars on Futuristic Toxicology in collaboration with Rosalind Franklin University of Medical Sciences, Illinois Science and Technology Park and University of Connecticut
  • Aagami completes a busy and fruitful BioPharm America 2017 along with extended business trip to New York and Connecticut